Australia outlines roles and duties of IVD sponsors and manufacturers
This article was originally published in RAJ Devices
Australia's Therapeutic Goods Administration has issued more details on the conformity assessment process under its new in vitro diagnostics regulations that came into force in July last year1-3. Specifically, the TGA has published documents distinguishing between the responsibilities and obligations of IVD sponsors and manufacturers under the new framework.
You may also be interested in...
Citing challenges posed by the COVID-19 pandemic, EU regulators have extended the deadline for companies to finish nitrosamine-related risk evaluations.
The Australian health care products regulator is inviting feedback on proposed measures to clarify the boundary for software-based products that are captured under the regulatory framework for medical devices.
A draft EU guideline explains how companies can ensure that data from ongoing clinical trials remains relevant for regulatory decision-making despite problems posed by the COVID-19 pandemic.